Introduction. Transdermal testosterone patch (TTP) treatment produced statistically significant improvements in satisfying sexual activity (SSA), sexual desire, and personal distress in postmenopausal women suffering from hypoactive sexual desire disorder (HSDD), but clinical significance of these changes was not determined.
Aim. To quantify the magnitude of change in 3 principal outcomes measures determined by HSDD-patients as associated with the perception of meaningful benefit with TTP therapy.
Conclusions. Changes in sexual desire, SSA, and personal distress observed with transdermal testosterone patch treatment in surgically menopausal women with HSDD were clinically significant and were associated with a meaningful treatment benefit.
Aim. To quantify the magnitude of change in 3 principal outcomes measures determined by HSDD-patients as associated with the perception of meaningful benefit with TTP therapy.
Conclusions. Changes in sexual desire, SSA, and personal distress observed with transdermal testosterone patch treatment in surgically menopausal women with HSDD were clinically significant and were associated with a meaningful treatment benefit.